Project Grant R01AG097480
- Federal Project Grant Award Summary Mayo Clinic received a $739,562 project grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 15, 2025, through May 31, 2029. The grant funds research investigating epigenetic regulation of donor heart preservation mediated by BRD4 (bromodomain-containing protein 4), a member of the bromodomain and extraterminal domain (BET) family of epigenetic readers. The...
- Federal Grant Award Summary Mayo Clinic received a $441,100 Project Grant from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective August 1, 2025, through July 31, 2027. The award funds a multiomic analysis research initiative focused on characterizing the downstream molecular effects of telomere length across individual chromosome arms in healthy human cells and telomere biology disorder patients. Specifically, the research employs TeloGator, a novel...
- Federal Project Grant Award Summary Mayo Clinic received a $680,583 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective August 1, 2025, through May 31, 2029. The grant funds research to discover aging-associated genetic modifiers and develop therapeutic interventions for anthracycline-induced cardiotoxicity (AIC), a cumulative dose-dependent cardiac side effect that limits the clinical use of...
- Federal Grant Award Summary Mayo Clinic received a $3.75 million Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866) effective May 15, 2025, with completion expected April 30, 2030. This research initiative investigates the effects of premenopausal bilateral oophorectomy (PBO) on imaging biomarkers associated with Alzheimer's disease and cerebrovascular disease in women. The project will enroll 400 women (200 with prior PBO and 200 without)...
- Federal Grant Award Summary Mayo Clinic Arizona received a $695,997 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 18, 2025, with a completion date of May 31, 2029. The award funds research investigating the role of Programmed Cell Death 4 (PDCD4) in doxorubicin-induced cardiotoxicity, a significant health concern for cancer survivors receiving anthracycline-based chemotherapy. The research...
- Federal Grant Award Summary Mayo Clinic received a $756,906 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025 through June 30, 2029. The award supports a population-based study utilizing deep learning (artificial intelligence) algorithms to detect and quantify breast arterial calcification (BAC) from two-dimensional and three-dimensional mammogram images. The research...
- Federal Grant Award Summary Mayo Clinic Arizona received a $160,092 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective December 21, 2025, with completion targeted for July 1, 2027. The award funds a multisite, longitudinal research study designed to characterize sleep health, sleep disorders, and cognitive functioning in heart transplant recipients. The research addresses a significant...
- Federal Grant Award Summary Mayo Clinic has been awarded $441,100 by the National Institute on Aging under the Aging Research program (CFDA 93.866) for a two-year project grant period from July 1, 2025, through June 30, 2027. The project, titled "Digital Detection of Handwriting Impairments in Patients with Atypical Alzheimer's Disease and Frontotemporal Dementia," seeks to develop and validate digital tools for analyzing handwriting samples as a diagnostic aid for neurodegenerative...
- Federal Grant Award Summary Mayo Clinic received a $736,006 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for a Phase 1 clinical trial of biologically engineered growing heart conduit designed to repair discontinuous pulmonary arteries. The award, dated September 1, 2025, with completion targeted for August 31, 2026, represents DHA investment in advanced biomedical research aimed at developing innovative therapeutic...
- Federal Project Grant Award Summary Mayo Clinic received a $150,000 project grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 15, 2025, with a completion date of August 31, 2026. The grant supports research investigating the clinical significance of somatic mosaic states in telomere biology disorders (TBD), a multisystem condition characterized...
Mayo Clinic received a $660,157 Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded February 1, 2026, with completion scheduled for January 31, 2031. The project investigates the role of BRD4 (Bromodomain and Extraterminal Domain protein 4) in enhancing the preservation quality of donor hearts from older individuals through three-dimensional chromosomal restructuring. The research addresses a critical clinical need: while heart transplantation is the standard treatment for end-stage heart failure, a substantial portion of available donor hearts—particularly those from donors over 55 years of age—are rejected due to the risk of primary graft dysfunction. The study delivers scientific research products including molecular characterization of aging biology in donor heart preservation, experimental validation of BRD4 inhibition strategies, and chromatin analysis demonstrating how BRD4-associated chromatin loops affect heart function following preservation-reperfusion injury. The research deliverables encompass mechanistic understanding of how BRD4 senses histone acetylation increases in aging hearts and contributes to transplant failure, with potential therapeutic applications through BRD4 inhibition via compounds such as JQ1. By expanding the molecular understanding of aging's impact on donor heart quality, this project aims to expand the viable donor heart pool beyond traditional age thresholds, thereby increasing transplant availability for patients with end-stage heart failure. The five-year project is performed at Mayo Clinic's Rochester, Minnesota campus.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $660.2k | 1/28/26 |